{"id":404040,"date":"2020-12-21T16:18:17","date_gmt":"2020-12-21T21:18:17","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=404040"},"modified":"2020-12-21T16:18:17","modified_gmt":"2020-12-21T21:18:17","slug":"cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board\/","title":{"rendered":"Cardiff Oncology Announces the Appointment of Dr. Rodney Markin as Chairman of the Board"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">SAN DIEGO<\/span>, <span class=\"xn-chron\">Dec. 21, 2020<\/span> \/PRNewswire\/ &#8212;\u00a0<b>Cardiff Oncology, Inc. <\/b>(Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-resistant prostate cancer and leukemia, today announced that Dr. <span class=\"xn-person\">Thomas Adams<\/span> has stepped down from his positions as Executive Chairman and Chairman of the Board of Directors, effective immediately. Dr. Adams will continue to serve on the Board as a Director. Dr. <span class=\"xn-person\">Rodney Markin<\/span> has been appointed by the Board of Directors as the Company&#8217;s new Chairman of the Board.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1165624\/Cardiff_Oncology_Inc_Logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1165624\/Cardiff_Oncology_Inc_Logo.jpg\" title=\"Cardiff Oncology is a clinical-stage biotechnology company and our mission is to develop new treatment options for cancer patients in indications with the greatest medical need. Our goal is to overcome resistance, improve response to treatment and increase overall survival. Our investigational drug, onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, is being evaluated in combination with standard-of-care chemotherapy and targeted therapeutics. We are assessing tumor genomics and using our expertise in biomarker technology to rapidly evaluate patient response to treatment. (PRNewsfoto\/Cardiff Oncology, Inc.)\" alt=\"Cardiff Oncology is a clinical-stage biotechnology company and our mission is to develop new treatment options for cancer patients in indications with the greatest medical need. Our goal is to overcome resistance, improve response to treatment and increase overall survival. Our investigational drug, onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, is being evaluated in combination with standard-of-care chemotherapy and targeted therapeutics. We are assessing tumor genomics and using our expertise in biomarker technology to rapidly evaluate patient response to treatment. (PRNewsfoto\/Cardiff Oncology, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>&#8220;On behalf of the entire Board, I would like to thank Tom for his leadership and dedication to the Company over the last twelve years,&#8221; said Dr. <span class=\"xn-person\">Rodney Markin<\/span>. &#8220;Tom&#8217;s contributions have enabled the Company to transition from a molecular diagnostics company and pioneer in liquid biopsy technology to a drug development company that is successfully advancing multiple clinical programs in some of the most difficult-to-treat cancers. We wish Tom the very best moving forward and are pleased that he is continuing in his role as a member of the Board.&#8221;<\/p>\n<p>&#8220;I feel fortunate to have spent the past seven years working alongside Tom, one of the great leaders in biotech,&#8221; added <span class=\"xn-person\">Mark Erlander<\/span>, chief executive officer of Cardiff Oncology. &#8220;As we turn our attention to 2021, the management team looks forward to working with Rod and the entire Board to execute our strategy and achieve our goals.&#8221;<\/p>\n<p>\n        <b>About Cardiff Oncology, Inc.<br \/><\/b>Cardiff Oncology (formerly Trovagene, Inc.) is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need.\u00a0 Our goal is to overcome resistance, improve response to treatment and increase overall survival.\u00a0 We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics.\u00a0 Our clinical development programs incorporate tumor genomics and biomarker technology to enable assessment of patient response to treatment. We have three ongoing clinical programs that are demonstrating the safety and efficacy of onvansertib: a Phase <span class=\"xn-money\">1b<\/span>\/2 study of onvansertib in combination with FOLFIRI\/Avastin\u00ae in KRAS-mutated metastatic colorectal cancer (mCRC); a Phase 2 study of onvansertib in combination with Zytiga\u00ae (abiraterone)\/prednisone in metastatic castration-resistant prostate cancer (mCRPC); and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia (AML). For more information, please visit <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3019933-1&amp;h=4260168398&amp;u=https%3A%2F%2Fwww.cardiffoncology.com%2F&amp;a=https%3A%2F%2Fwww.cardiffoncology.com\" rel=\"nofollow noopener noreferrer\">https:\/\/www.cardiffoncology.com<\/a>. \u00a0\u00a0 <\/p>\n<p>\n        <b><br \/>\n          <u>Cardiff Oncology Contact:<br \/><\/u><br \/>\n        <\/b><br \/>\n        <span class=\"xn-person\">Vicki Kelemen<\/span><br \/>\n        <br \/>Chief Operating Officer<br \/>858-952-7652<br \/><a target=\"_blank\" href=\"mailto:vkelemen@cardiffoncology.com\" rel=\"nofollow noopener noreferrer\">vkelemen@cardiffoncology.com<\/a><\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA31086&amp;sd=2020-12-21\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board-301197030.html\">http:\/\/www.prnewswire.com\/news-releases\/cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board-301197030.html<\/a><\/p>\n<p>SOURCE  Cardiff Oncology, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA31086&amp;Transmission_Id=202012211615PR_NEWS_USPR_____LA31086&amp;DateId=20201221\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire SAN DIEGO, Dec. 21, 2020 \/PRNewswire\/ &#8212;\u00a0Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-resistant prostate cancer and leukemia, today announced that Dr. Thomas Adams has stepped down from his positions as Executive Chairman and Chairman of the Board of Directors, effective immediately. Dr. Adams will continue to serve on the Board as a Director. Dr. Rodney Markin has been appointed by the Board of Directors as the Company&#8217;s new Chairman of the Board. &#8220;On behalf of the entire Board, I would like to thank Tom for his leadership and dedication to the Company over the last twelve years,&#8221; &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cardiff Oncology Announces the Appointment of Dr. Rodney Markin as Chairman of the Board&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-404040","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cardiff Oncology Announces the Appointment of Dr. Rodney Markin as Chairman of the Board - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cardiff Oncology Announces the Appointment of Dr. Rodney Markin as Chairman of the Board - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN DIEGO, Dec. 21, 2020 \/PRNewswire\/ &#8212;\u00a0Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-resistant prostate cancer and leukemia, today announced that Dr. Thomas Adams has stepped down from his positions as Executive Chairman and Chairman of the Board of Directors, effective immediately. Dr. Adams will continue to serve on the Board as a Director. Dr. Rodney Markin has been appointed by the Board of Directors as the Company&#8217;s new Chairman of the Board. &#8220;On behalf of the entire Board, I would like to thank Tom for his leadership and dedication to the Company over the last twelve years,&#8221; &hellip; Continue reading &quot;Cardiff Oncology Announces the Appointment of Dr. Rodney Markin as Chairman of the Board&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-21T21:18:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1165624\/Cardiff_Oncology_Inc_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cardiff Oncology Announces the Appointment of Dr. Rodney Markin as Chairman of the Board\",\"datePublished\":\"2020-12-21T21:18:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board\\\/\"},\"wordCount\":445,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1165624\\\/Cardiff_Oncology_Inc_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board\\\/\",\"name\":\"Cardiff Oncology Announces the Appointment of Dr. Rodney Markin as Chairman of the Board - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1165624\\\/Cardiff_Oncology_Inc_Logo.jpg\",\"datePublished\":\"2020-12-21T21:18:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1165624\\\/Cardiff_Oncology_Inc_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1165624\\\/Cardiff_Oncology_Inc_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cardiff Oncology Announces the Appointment of Dr. Rodney Markin as Chairman of the Board\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cardiff Oncology Announces the Appointment of Dr. Rodney Markin as Chairman of the Board - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board\/","og_locale":"en_US","og_type":"article","og_title":"Cardiff Oncology Announces the Appointment of Dr. Rodney Markin as Chairman of the Board - Market Newsdesk","og_description":"PR Newswire SAN DIEGO, Dec. 21, 2020 \/PRNewswire\/ &#8212;\u00a0Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-resistant prostate cancer and leukemia, today announced that Dr. Thomas Adams has stepped down from his positions as Executive Chairman and Chairman of the Board of Directors, effective immediately. Dr. Adams will continue to serve on the Board as a Director. Dr. Rodney Markin has been appointed by the Board of Directors as the Company&#8217;s new Chairman of the Board. &#8220;On behalf of the entire Board, I would like to thank Tom for his leadership and dedication to the Company over the last twelve years,&#8221; &hellip; Continue reading \"Cardiff Oncology Announces the Appointment of Dr. Rodney Markin as Chairman of the Board\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-21T21:18:17+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1165624\/Cardiff_Oncology_Inc_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cardiff Oncology Announces the Appointment of Dr. Rodney Markin as Chairman of the Board","datePublished":"2020-12-21T21:18:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board\/"},"wordCount":445,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1165624\/Cardiff_Oncology_Inc_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board\/","name":"Cardiff Oncology Announces the Appointment of Dr. Rodney Markin as Chairman of the Board - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1165624\/Cardiff_Oncology_Inc_Logo.jpg","datePublished":"2020-12-21T21:18:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1165624\/Cardiff_Oncology_Inc_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1165624\/Cardiff_Oncology_Inc_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-announces-the-appointment-of-dr-rodney-markin-as-chairman-of-the-board\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cardiff Oncology Announces the Appointment of Dr. Rodney Markin as Chairman of the Board"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/404040","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=404040"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/404040\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=404040"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=404040"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=404040"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}